S80459 |
Varespladib (LY315920) |
源葉(MedMol) | 98% |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.629 ml | 13.144 ml | 26.289 ml |
5 mM | 0.526 ml | 2.629 ml | 5.258 ml |
10 mM | 0.263 ml | 1.314 ml | 2.629 ml |
50 mM | 0.053 ml | 0.263 ml | 0.526 ml |
- 提示:詳情請(qǐng)下載說明書。
- 產(chǎn)品描述: Varespladib (LY315920) is a potent and selective group IIA, secretory phospholipase A2 (sPLA2) inhibitor with an IC50 of 9 nM. Varespladib exhibits the significant inhibitory effect on sPLA2 activity in serum from various species including rat, rabbit, guinea pig and human with IC50s of 8.1 nM, 5.0 nM, 3.2 nM and 6.2 nM, respectively
- 靶點(diǎn): sPLA2:9 nM (IC50);Phospholipase
- 體內(nèi)研究:
Varespladib treatment inhibits human sPLA2-induced release of thromboxane A2 (TXA2) from isolated guinea pig lung bronchoalveolar lavage cells with an IC50 of 0.79 μM. And the ED50 for Varespladib is 16.1 mg/kg
- 參考文獻(xiàn):
1. Snyder DW, et al. Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI. J Pharmacol Exp Ther. 1 2. Hori Y, et al. Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
- 溶解性: DMSO : 100 mg/mL (262.89 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble)
- 保存條件: -20℃
- 配置溶液濃度參考:
1mg 5mg 10mg 1 mM 2.629 ml 13.144 ml 26.289 ml 5 mM 0.526 ml 2.629 ml 5.258 ml 10 mM 0.263 ml 1.314 ml 2.629 ml 50 mM 0.053 ml 0.263 ml 0.526 ml
- 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號(hào):
本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:
質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)